PBS-Bio uncovers how Unibioscreen drug kills cancer

Discovery could help doctors decide which patients would benefit most

MESA, Ariz. - March 8, 2011 - Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways - the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.

# # #

About Unibioscreen
Unibioscreen is a Belgian private specialist oncology company with focus on innovative "first in class" oncology therapeutics. Unibioscreen has successfully discovered, patented and developed a drug candidate currently in clinical trials in cancer patients.
Unibioscreen built its competitive edge on exploiting through hemi-synthesis the structure activity relationship (SAR) of natural product chemistry and through development and use of unique technologies and demanding orthotopic models of cancer.
More information is available on: www.unibioscreen.com.

Press Contacts:
Steve Weitman
Chief Medical Officer
[email protected]


About PBS-Bio
Predictive Biomarker Sciences Inc. (PBS-Bio) is a privately held corporation based in Mesa, Arizona, and founded in 2006 with funding from private investors, mostly based in Arizona. It is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen). The PBS-Bio/TGen collaborative team includes: Dr. Michael Bittner, a biologist, Co-Director of TGen's Computational Biology Division, and Principal Investigator at TGen for the PBS-Bio technology; Dr. Edward Dougherty, an electrical engineer and the other Co-Director of TGen's Computational Biology Division; and Dr. Edward Smith, a medical doctor, an adjunct faculty member of TGen, and co-founder and CEO of PBS-Bio. The three began their collaborations while working under TGen President and Research Director Dr. Jeffrey Trent when Dr. Trent was the Scientific Director of the National Human Genomics Research Institute in Bethesda, Md. Their professional relationships continued after TGen was founded in Phoenix in 2002. For more information, please visit: pbs-bio.com.

Press Contact:
Dr. Edward Smith, M.D.
President and CEO
[email protected]

Media Contact

RSS Feed